Trials / Completed
CompletedNCT00215514
Adjuvant Chemoradiation Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma
A Pilot Study of Adjuvant Chemoradiation After Resection of Gastric Or Gastroesophageal Junction Adenocarcinoma
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Dana-Farber Cancer Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this trial is to determine how well patients with gastric or gastroesophageal junction adenocarcinoma respond to chemotherapy with epirubicin, cisplatin and 5-fluorouracil followed by continuous infusion 5-fluorouracil chemotherapy given along with radiation therapy.
Detailed description
* Patients will receive epirubicin and cisplatin intravenously on day 1 of treatment. 5-fluorouracil will be given continuously by intravenous infusion bia a portable ambulatory pump (CADD pump) for 21 days. This cycle of chemotherapy will take 21 days (3 weeks). Once it is complete there will be one week without therapy. * Once the patient has recovered from any side-effects from the chemotherapy they will start the combination chemoradiation therapy, 5-fluorouracil and radiation. The radiation will be directed to the upper abdomen in the area where the stomach tumor has been located. The radiation therapy will be given five days a week for a total of five weeks. During these five weeks patients will receive 5-fluorouracil continuously by CADD pump. * After completion of combination chemoradiation therapy there will be a three to four week rest period followed by 2 additional chemotherapy cycles identical to the first chemotherapy cycle. * The following tests and procedures will be performed: physical examination every 4 weeks except during the chemoradiation therapy when it will be done weekly; blood tests every week during chemotherapy and chemoradiation; CT scans and chest x-rays done before therapy, at the end of therapy, and yearly for 2 years; noninvasive testing to evaluate kidney function before starting the study. * The program of chemotherapy and radiation therapy will last approximately 30 weeks. After all treatment is completed, patients will return for physical examinations and blood tests every 3 months for 3 years; then every 6 months for 2 years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Epirubicin | Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> One-week rest --\> External Beam Radiation Therapy plus 5-FU CI --\> Four-week rest --\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21). |
| DRUG | Cisplatin | Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> One-week rest --\> External Beam Radiation Therapy plus 5-FU CI --\> Four-week rest --\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21). |
| DRUG | 5-Fluorouracil (5-FU) | Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> One-week rest --\> External Beam Radiation Therapy plus 5-FU CI --\> Four-week rest --\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21). |
| PROCEDURE | Radiation | Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> One-week rest --\> External Beam Radiation Therapy plus 5-FU CI --\> Four-week rest --\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21). |
Timeline
- Start date
- 2000-09-01
- Primary completion
- 2003-11-01
- Completion
- 2014-07-01
- First posted
- 2005-09-22
- Last updated
- 2014-07-29
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00215514. Inclusion in this directory is not an endorsement.